Lupin’s Nagpur injectable facility has received an Establishment Inspection Report from the US FDA, confirming compliance with manufacturing norms for drug-device combination products after a June 2024 inspection.
Lupin’s Nagpur injectable facility has received an Establishment Inspection Report from the US FDA, confirming compliance with manufacturing norms for drug-device combination products after a June 2024 inspection.